

Supplementary Table 1. Difference of biochemical markers between before and after treatment

Variable	Rosuvastatin 5 mg/day (n=47)	Rosuvastatin 5 mg+Ezetimibe 10 mg/day (n=45)	P value ^a	P value ^b
LDL-C, mg/dL	-47.60±30.38	-69.38±25.46	<0.001	
Triglyceride, mg/dL	-40.02±72.98	-49.78±95.74	0.583	0.717
HDL-C, mg/dL	1.40±7.87	0.98±8.07	0.789	0.854
Fasting plasma glucose, mg/dL	-20.23±86.66	-5.45±47.11	0.320	0.141
HbA1c, %	-0.26±1.20	0.06±1.10	0.190	0.069
Fasting insulin, mIU/L	-1.90±9.71	-6.23±11.00	0.048	0.148
HOMA-IR	-0.74±7.01	-2.49±5.08	0.179	0.494
HOMA-β	-19.34±87.75	-27.40±61.51	0.616	0.671
sICAM-1, ng/mL	19.67±42.30	32.54±59.16	0.232	0.299
PRDX4, pg/mL	600.95±3,221.43	2,302.12±4,647.28	0.102	0.180

Values are presented as mean ± standard deviation.

LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; HbA1c, glycosylated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; sICAM-1, soluble intercellular adhesion molecule-1; PRDX4, peroxiredoxin-4.

^aP value from Student's *t*-test between rosuvastatin group and rosuvastatin/ezetimibe group, ^bP value from analysis of covariance after adjusted for change in LDL-C level between before and after treatment.